Prosp Pharma
Concise Prescribing Info
Candesartan cilexetil
Essential HTN. Heart failure & impaired left ventricle systolic function (left ventricular ejection fraction ≤40%), as add-on therapy to ACE inhibitor or when ACE inhibitors are not tolerated.
Dosage/Direction for Use
HTN Initial & maintenance dose: 8 mg once daily. May be increased to 16 mg once daily. Max: 32 mg once daily if not sufficiently controlled after 4 wk. Patients w/ intravascular vol depletion, severe renal impairment (CrCl <30 mL/min/1.73 m2), or mild to moderate hepatic impairment Initial dose: 4 mg. Heart failure Initially 4 mg once daily. Up-titrated to target dose: 32 mg once daily or highest tolerated dose.
May be taken with or without food.
Hypersensitivity. Severe hepatic impairment &/or cholestasis. Pregnancy & lactation.
Special Precautions
Renal artery stenosis. Concomitant use w/ drugs affecting renin-angiotensin-aldosterone system (eg, angiotensin II receptor antagonist); ACE inhibitor; K-sparing diuretics, K supplements, salt substitutes containing K, or other drugs that may increase K levels (eg, heparin). Periodically monitor serum K & creatinine levels. Periodically assess renal function of patients w/ heart failure especially in the elderly. Patients who are intravascularly vol depleted (eg, those receiving high dose diuretics); monitor BP in patients undergoing hemodialysis; w/ severe CHF or underlying renal disease. Correction of hypovolemia should be attempted. End-stage renal impairment (CrCl <15 mL/min). Serum creatinine >3 mg/dL. Kidney transplantation. Hypotension may occur in heart failure patients. Pregnancy (especially in 2nd & 3rd trimesters) & lactation.
Adverse Reactions
Leukopenia, neutropenia, agranulocytosis; hyperkalaemia, hyponatraemia; dizziness, headache; nausea; increased liver enzymes, abnormal hepatic function, hepatitis; angioedema, rash, urticaria, pruritus; back pain, arthralgia, myalgia; renal impairment, including renal failure.
Drug Interactions
K levels may be increased w/ K-sparing diuretics, K supplements, salt substitutes containing K, or other drugs (eg, heparin). Increase conc & toxicity of lithium. Attenuated antihypertensive effect w/ NSAIDs (ie, selective COX-2 inhibitors, acetylsalicylic acid & non-selective NSAIDs). Increased risk of renal function worsening w/ NSAIDs.
ATC Classification
C09CA06 - candesartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Kanda-16 tab 16 mg
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in